U.S. Spect products | Cardiology

Kit for the Preparation of Technetium Tc99m Sestamibi Injection

This information is intended for U.S. healthcare professionals only.

Product information

Curium Tc99m Sestamibi—a choice for nuclear medicine professionals that provides imaging quality and economic value in a single product offering.

Tc99m Sestamibi is fully substitutable for the brand name product.

Curium is an experienced manufacturer of generic pharmaceuticals with a strong history in the radiopharmaceutical industry.

Tc 99m Sestamibi delivers a high degree of diagnostic accuracy.1,2

Curium seeks to provide value to nuclear medicine professionals.

Indication & Usage

Technetium Tc99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent’s labeling).

It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia.

Technetium Tc99m Sestamibi is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass.

Technetium Tc99m Sestamibi is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy.

Important risk information

Warnings and precautions

  • Death infrequently has occurred 4 to 24 hours after Technetium Tc99m Sestamibi use and is usually associated with exercise stress testing. Continuous monitoring and treatment should be assured in patients with known or suspected cardiac disease.
  • Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction and cerebrovascular events. Caution should be used when pharmacologic stress is selected as an alternative to exercise; it should be used when indicated and in accordance with the pharmacologic stress agent’s labeling.
  • Technetium Tc99m Sestamibi has been rarely associated with acute severe allergic and anaphylactic events of angioedema and generalized urticaria. In some patients the allergic symptoms developed on the second injection during Tc99m Sestamibi imaging. Caution should be used and emergency equipment should be available when administering Technetium Tc99m Sestamibi. Patients should be asked about the possibility of allergic reactions to the drug before administration of Technetium Tc99m Sestamibi.
  • The contents of the vial are intended only for use in the preparation of Technetium Tc99m Sestamibi and are not to be administered directly to the patient without first undergoing the preparative procedure.
  • Radioactive drugs must be handled with care and appropriate safety measures should be used to minimize radiation exposure to clinical personnel and patients.
  • Contents of the kit before preparation are not radioactive. However, after the Sodium Pertechnetate Tc99m Injection is added, adequate shielding of the final preparation must be maintained and care should be taken to minimize radiation exposure.
  • It is essential to follow directions carefully and to adhere to strict aseptic procedures during preparation.
  • Technetium Tc99m labeling reactions depend on maintaining the stannous ion in the reduced state. Hence, Sodium Pertechnetate Tc99m Injection containing oxidants should not be used.
  • Technetium Tc99m Sestamibi should not be used more than six hours after preparation.
  • Radiopharmaceuticals should be used only by physicians whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.
  • Stress testing should be performed only under the supervision of a qualified physician and in a laboratory equipped with appropriate resuscitation and support apparatus.

Adverse reactions

  • Serious adverse reactions include arrhythmia, angioedema, angina, seizure, chest pain, severe hypersensitivity, dyspnea and death.
  • Common adverse reactions include taste perversion, changes in special senses and disorders of body as a whole.

Use in specific populations

  • Safety and effectiveness in the pediatric population have not been established.
  • Limited available data with Technetium Tc99m Sestamibi use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; however, all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose.
  • Interruption of breastfeeding is not necessary, however, a lactating woman should consider restricting close contact with her breast fed infant to a maximum of 5 hours in the 24 hour period after Technetium Tc99m Sestamibi administration to minimize radiation exposure.

Frequently asked questions

The reconstituted vial should be used within six (6) hours of preparation.

150 mCi (volume 1 to 3 mL), see Prescribing Information for additional details.

Technetium Tc99m Sestamibi can be ordered through your local Sales Representative, or our Customer Service Department at 888.744.1414, option 1 then option 2. Orders are accepted Monday – Friday, 7:00 am to 5:00 pm. CST

Call Curium Pharmacovigilance / Product Monitoring Department at 866.789.2211

How is this product supplied




Kit: 24 months post manufacture
Reconstituted vial: 6 hours from time of preparation

Storage conditions

Kit: Controlled room temperature 15° to 25°C (59° to 77°F); protect from light
Reconstituted vial: Controlled room temperature 15° to 25°C (59° to 77°F)

Order information

Description Qty Unit Size Order # NDC
Tc99m Sestamibi kit, 5 vial 1 Kit 5 vial N092B0 69945-092-20
Tc99m Sestamibi kit, 30 vial 1 Kit 30 vial N092D0 69945-092-40


Klocke FJ, Baird MG, Bateman TM, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2003:10-11. 2Kit for the Preparation of Technetium Tc99m Sestamibi Injection package insert. Maryland Heights, MO: Curium US LLC; 2022.

Product contact information

Maryland Heights